Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

计划入组 21 人 · 首次发布于 2025 年 2 月 26 日

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

计划入组 6 人 · 首次发布于 2014 年 9 月 30 日

Effect of Sancao Lichang Decoction in the treatment of diarrhea irritable bowel syndrome based on TLR4/MyD88/NF-?B signaling pathway

MYD88 mutant lymphoma therapy

Sanofi's KT-474 Shows Promise as First-in-Class MyD88 Inhibitor for Inflammatory Diseases

SPIMA Therapeutics Launches with Exclusive License for Myddosome Inhibitor SPM001

Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise